Prevention of false resistance results obtained in testing the susceptibility of Mycobacterium tuberculosis to pyrazinamide with the bactec MGIT 960 system using a reduced inoculum

Journal of Clinical Microbiology

Volumn 51, Issue 1, 2013, Pages 291-294

  Piersimoni, Claudio ^a   Mustazzolu, Alessandro ^b   Giannoni, Federico ^b   Bornigia, Stefano ^a   Gherardi, Giancarlo ^a   Fattorini, Lanfranco ^b  

^a United Hospitals   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ANALYTICAL EQUIPMENT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM EXAMINATION; BACTERIUM ISOLATION; BIOASSAY; CONTROLLED STUDY; FALSE POSITIVE RESULT; GENE MUTATION; INOCULATION; MINIMUM INHIBITORY CONCENTRATION; MUTATIONAL ANALYSIS; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PNCA GENE; PRIORITY JOURNAL; RPSA GENE; SENSITIVITY AND SPECIFICITY;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; FALSE POSITIVE REACTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; TUBERCULOSIS;

MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS COMPLEX;

EID: 84871675216     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01838-12     Document Type: Article

References (27)

1. Yew WW, Lange C, Leung CC. 2011. Treatment of tuberculosis: update 2010. Eur. Respir. J. 37:441-462.
2. Konno K, Feldman FM, McDermott W. 1967. Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am. Rev. Respir. Dis. 95:461-469.
3. Zhang Y, Mitchison D. 2003. The curious characteristics of pyrazinamide: a review. Int. J. Tuberc. Lung Dis. 7:6-21. (Pubitemid 36427026)
4. Mestdagh M, Fonteyne PA, Realini L, Rossau R, Jannes G, Mijs W, De Smet KAL, Portaels F, Van den Eeckhout E. 1999. Relationship between pyrazinamide resistance, loss of pyrazinamidase activity, and mutations in the pncA locus in multidrug-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 43:2317-2319. (Pubitemid 29421225)
5. Miller MA, Thibert L, Desjardins F, Siddiqi SH, Dascal A. 1995. Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide: comparison of BACTEC method with pyrazinamidase assay. J. Clin. Microbiol. 33:2468-2470.
6. Cheng SJ, Thibert L, Sanchez T, Heifets L, Zhang Y. 2000. pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada. Antimicrob. Agents Chemother. 44:528-532. (Pubitemid 30117936)
7. Hirano K, Takahashi M, Kazumi Y, Fukasawa Y, Abe C. 1997. Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis. Tuber. Lung Dis. 78:117-122. (Pubitemid 28080549)
8. Scorpio A, Lindholm-Levy P, Heifets L, Gilman R, Siddiqi S, Cynamon M, Zhang Y. 1997. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 41:540-543. (Pubitemid 27098400)
9. Heifets L. 2002. Susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J. Med. Microbiol. 51:11-12. (Pubitemid 34060127)
10. Salfinger M, Heifets L. 1988. Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method. Antimicrob. Agents Chemother. 7:1002-1004.
11. Butler WR, Kilburn JO. 1982. Improved method for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J. Clin. Microbiol. 16:1106-1109. (Pubitemid 13250675)
12. Heifets LB. 1991. Drug susceptibility tests in the management of chemotherapy of tuberculosis, p 89-121. In Heifets LB (ed), Drug susceptibility in the chemotherapy of mycobacterial infections. CRC Press, Inc., Boca Raton, FL.
13. CLSI. 2011. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes, 2nd ed. Approved standard. CLSI document M24-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
14. Chedore P, Bertucci L, Wolfe J, Sharma M, Jamieson F. 2010. Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J. Clin. Microbiol. 48:300-301.
15. Pandey S, Newton S, Upton A, Roberts S, Drinkovic D. 2009. Characterisation of pncA mutations in clinical Mycobacterium tuberculosis isolates in New Zealand. Pathology 41:582-584.
16. Simons SO, van Ingen J, van der Laan T, Mulder A, Dekhuijzen PNR, Boeree MJ, van Soolingen D. 2012. Validation of pncA gene sequencing in combination with the Mycobacterial Growth Indicator Tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide J. Clin. Microbiol. 50:428-434.
17. Huang TS, Lee SSJ, Tu HZ, Huang WK, Chen YS, Huang CK, Wann SR, Lin HH, Liu YC. 2003. Correlation between pyrazinamide activity and pncA mutations in Mycobacterium tuberculosis isolates in Taiwan. Antimicrob. Agents Chemother. 47:3672-3673.
18. Shi W, Zhang X, Jiang X, Yuan H, Seok-Lee J, Barry SCE III, Wang H, Zhang W, Zhang Y. 2011. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 16:1630-1632.
19. CLSI. 2008. Laboratory detection and identification of mycobacteria; approved guideline. CLSI document M48-A. Clinical and Laboratory Standards Institute, Wayne, PA.
20. Richter E, Weizenegger M, Rusch-Gerdes S, Niemann S. 2003. Evaluation of GenoType MTBC assay for differentiation of clinical Mycobacterium tuberculosis complex isolates. J. Clin. Microbiol. 41:2672-2675. (Pubitemid 36712488)
21. Becton, Dickinson and Company. 1999. Bactec MGIT 960 system user's manual. Becton, Dickinson and Company, Sparks, MD.
22. Siddiqi S. 2004. BACTEC 460 TB (radiometric) system. Indirect susceptibility testing for Mycobacterium tuberculosis, p 7.8.1.1-7.8.1.7. In Isenberg HD (ed), Clinical microbiology procedures handbook, 2nd ed, vol 2. American Society for Microbiology, Washington, DC.
23. Juréen P, Werngren J, Toro JC, Hoffner S. 2008. Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 52:1852-1854. (Pubitemid 351614686)
24. Zhang Y, Permar S, Sun Z. 2002. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J. Med. Microbiol. 51:42-49.
25. Werngren J, Sturegård E, Juréen P, Ängeby K, Hoffner S, Schön T. 2012. Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing Antimicrob. Agents Chemother. 56:1253-1257.
26. Chang KC, Yew WW, Zhang Y. 2011. Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses. Antimicrob. Agents Chemother. 55:4499-4505.
27. Sekiguchi JI, Nakamura T, Miyohi-Akiyama T, Kirikae F, Kobayashi I, Augustinowicz-Kopec E, Zwolska Z, Morita K, Suetake T, Yoshida H, Kato S, Mori T, Kiikae T. 2007. Development and evaluation of a line probe assay for rapid identification of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis strains. J. Clin. Microbiol. 45:2802-2807. (Pubitemid 47417318)